In a randomized, double blind, crossover study, 10 patients with stable exercise-induced angina pectoris were studied during acute and sustained therapy with oral isosorbide dinitrate. Circulatory changes and exercise performance were evaluated before and 2 and 6 hours after medication. Sublingual nitroglycerin was administered 30 minutes after the 2 and 6 hour exercise tests and the exercise test was repeated after another 5 minutes.
In a randomized, double blind, crossover study, 10 patients with stable exercise-induced angina pectoris were studied during acute and sustained therapy with oral isosorbide dinitrate. Circulatory changes and exercise performance were evaluated before and 2 and 6 hours after medication. Sublingual nitroglycerin was administered 30 minutes after the 2 and 6 hour exercise tests and the exercise test was repeated after another 5 minutes.
Systolic blood pressure at rest 2 hours after isosorbide dinitrate decreased by 25% during the acute phase, but by only 11% during the sustained phase (probability [p] < 0.05). Systolic blood pressure was not decreased further by nitroglycerin during acute therapy, but was decreased during sustained therapy (p < 0.05). Six hours after isosorbide dinitrate administration, systolic blood pressure remained significantly below the control value during sustained therapy. Treadmill walking time to moderate angina was significantly prolonged 2 hours Nitroglycerin administered sublingually has long been recognized as an effective antianginal agent, but controversy has existed regarding the value of orally administered organic nitrate preparations, Studies by Needleman et a1. (I) suggested that the nitrates were ineffective after oral administration because of extensive first pass metabolic changes, However, numerous investigations have demonstrated that orally administered nitrates produce significant hemodynamic effects and benefit patients with angina pectoris (2) (3) (4) (5) (6) (7) and left ventricular dysfunction (8) (9) (10) ,
Further controversy exists regarding the development of nitrate tolerance. Animal experiments (11) (12) (13) (14) (15) (16) (17) (18) have shown a rapid attenuation of the hypotensive response during con-after isosorbide dinitrate administration during both the acute and sustained phases. During the sustained phase, there was no difference from control values after 6 hours. Nitroglycerin did not increase walking time 2 1/2 hours after isosorbide dinitrate during either acute (567 ± 122 versus 560 ± 119seconds) or sustained (582 ± 115versus 567 ± 129 seconds) therapy, but at 6 1/2 hours, nitroglycerin increased walking time from 473 ± 125 to 547 ± 107 seconds (p < 0.05) during sustained therapy.
This study demonstrates that 1) tolerance to the hemodynamic and antianginal effects of isosorbide dinitrate develops rapidly, 2) nitroglycerin does not further prolong exercise duration 2 1/2 hours after isosorbide dinitrate administration, 3) nitroglycerin prolongs exercise duration when isosorbide dinitrate is no longer exerting a beneficial effect, and 4) there is possible crosstolerance between isosorbide dinitrate and nitroglycerin. tinuous therapy with nitroglycerin, a phenomenon that is time-and dose-dependent. Clinical studies, however, have shown variable results. Some investigators (19, 20) reported that tolerance to the circulatory effects of the nitrates and cross-tolerance to nitroglycerin is well established within a few weeks; others (21) (22) (23) failed to demonstrate either tolerance to isosorbide dinitrate or cross-tolerance between isosorbide dinitrate and nitroglycerin. Studies from our laboratory (7, 24) have demonstrated that partial circulatory tolerance to isosorbide dinitrate and cross-tolerance to nitroglycerin develop rapidly during regular therapy with isosorbide dinitrate and that partial tolerance to the antianginal effects of isosorbide dinitrate during therapy is maintained for only 1 week.
In view of the conflicting evidence regarding nitrate tolerance and cross-tolerance among the organic nitrates, we undertook to reassess the development of tolerance to the circulatory and antianginal effects of isosorbide dinitrate. We attempted to determine whether therapy with this agent modifies the hemodynamic and antianginal effects of sublingual nitroglycerin. 
Methods
Study patients. Ten men, aged 51 to 63 years, with stable angina pectoris were studied. None of the patients was hypertensive, had clinical evidence of left ventricular dysfunction or had clinical or electrocardiographic evidence of previous myocardial infarction. Six patients had undergone coronary arteriography and were found to have more than 75% stenosis of at least one major coronary artery. Sublingual nitroglycerin was the only medication the patients were taking and this was not required on the days of the investigation. All patients had undergone repeated exercise testing and were familiar with this procedure. During the preliminary treadmill exercise test, all patients experienced angina and had horizontal or downsloping ST segment depression of 0.1 mV or more of at least 0.08 second duration. A computer-assisted system (Marquette Computer Assisted System for Exercise) was employed that displayed three simultaneous leads (V}, V 6 and aVF). The study was explained to each patient and informed written consent was obtained.
Design of investigation. The patients exercised on a treadmill following the Bruce multistage protocol (25) . On all tests they were encouraged to exercise to an end point of chest pain of moderate severity, similar to that at which they would normally stop and take nitroglycerin. During the study, some patients did not develop angina after drug administration and stopped exercise because of fatigue. In the absence of angina, this was considered the end point. Blood pressure, taken by sphygmomanometry, was recorded in the supine and standing positions before exercise, at 3 minute intervals during exercise and at the end of exercise. The treadmill walking time was also recorded at the end of exercise. The rate-pressure product at that time was calculated as the product of systolic blood pressure and heart rate.
Precautions were taken to control factors that can produce changes in exercise tolerance. The temperature in the laboratory was maintained between 20 and 22°C and the patients' apprehension was reduced by familiarization with the technique and the staff. The definitive studies were performed after an overnight fast and the patients did not smoke during the time of investigation. A light lunch without tea or coffee was provided at noon.
Acute phase. This phase of the study was placebo-controlled and double blind. A control exercise test was performed at 8:30 a.m., and at 9:00 a.m. the patient was randomized to receive either 30 mg of isosorbide dinitrate orally or a matching placebo. At 11:00 a.m., 2 hours after taking the medication, the exercise test was repeated. After 30 minutes, the patient received either 0.6 mg of sublingual nitroglycerin or sublingual placebo. Five minutes later, a third exercise test was performed. The schedule for the next 3 days was similar. On day 2, the patient received the same oral medication but the other sublingual medication. On days 3 and 4, the patient received the other oral medication and the sublingual medication was again randomized during these 2 days.
Sustained phase. This phase of the study was also placebo-controlled and double blind in design. The patient was given either placebo or isosorbide dinitrate. To reduce the likelihood of untoward side effects from isosorbide dinitrate, therapy with isosorbide dinitrate or placebo was initiated with 1/2 tablet (15 mg isosorbide dinitrate) 4 times daily for 3 days and then increased to 1 tablet (30 mg isosorbide dinitrate) 4 times daily for 1 week. Two patients continued to receive only a 15 mg dose of isosorbide dinitrate because of headaches. After 1 week of the maximal isosorbide dinitrate dose, the patient reported to the laboratory in the fasting state without taking the morning medication. A control exercise test was performed at 8:30 a.m. At 9:00 a.m., the patient was given the regularly scheduled medication. Two hours later, an exercise test was performed. After 30 minutes, the patient received either 0.6 mg of sublingual nitroglycerin or placebo, and 5 minutes later, a third exercise test was performed. At 3:00 p.m., 6 hours after oral medication, a fourth exercise test was performed. After 30 minutes, the patient received the same sublingual medication given earlier and after another 5 minutes, a final exercise test was performed. The patient then continued with the regularly scheduled oral medication and returned the next day before the morning dose. The schedule for that day was similar with the patient receiving the same oral medication but the opposite sublingual medication. The patient was then given the other oral medication, but following the same titration schedule and maintained on the maximal dose for 1 week. The patient subsequently returned for 2 days of testing with the schedule outlined previously.
Statistical analysis. Conventional statistical methods were used throughout the study. The significance of changes was studied by Student's t test for paired and unpaired data and by two-way analysis of variance. Probability (p) values less than 0.05 were considered significant. All data are expressed as mean ± standard deviation of the mean.
Results
All 10 patients completed the acute and sustained phases of the study without complication. None of the patients experienced angina at rest during the days of exercise testing. Nitroglycerin was not administered except as required by the protocol.
Acute Phase
Exercise tolerance (Table 1) . The control walking time was not significantly different during the 4 study days. A significant increase in walking time was observed 2 hours after oral isosorbide dinitrate but not after placebo. Sublin- gual nitroglycerin did not increase walking time in patients who had received oral isosorbide dinitrate, but did produce a significant increase in those who had received oral placebo. The walking time after nitroglycerin was similar to that recorded 2 hours after isosorbide dinitrate. Sublingual placebo produced no change in exercise tolerance. Blood pressure response ( Table 2 ). The standing systolic blood pressure was not significantly different before the control exercise test on the 4 study days. A significant decrease in systolic pressure was noted 2 hours after oral isosorbide dinitrate. After sublingual nitroglycerin, systolic pressure was significantly decreased in patients who had received oral placebo, but not in those given isosorbide dinitrate.
Rate-pressure product ( Table 2 ). The exercise ratepressure product at the point of moderate angina was not significantly different on the 4 study days during the control exercise test. Neither oral isosorbide dinitrate nor placebo altered the exercise rate-pressure product significantly.
However, there was a significant increase after nitroglycerin in patients who had received oral placebo, but not in those given isosorbide dinitrate.
Sustained Phase
Exercise tolerance (Table 3) . Walking time during the control exercise test was not significantly different on the 4 study days; however, a significant increase in walking time was present 2 hours, but not 6 112 hours, after isosorbide dinitrate administration. Walking time increased by 21% 2 hours after isosorbide dinitrate during this sustained phase, compared with 26% during the acute phase.
Sublingual nitroglycerin produced a significant increase in walking time in patients who had received placebo 2 1/2 hours earlier, but not in those given isosorbide dinitrate. When nitroglycerin was administered 6 1/2 hours after oral medication, there was a significant increase in walking time after both placebo and isosorbide dinitrate. The improve- ment in walking time after nitroglycerin was 26% in the group receiving placebo and 18% in those receiving sustained isosorbide dinitrate; these differences were not significant. The exercise end point after nitroglycerin was similar whether the patients were receiving isosorbide dinitrate or placebo or whether the tests were carried out 2 1/2 or 6 112 hours after the oral medication. Blood pressure response (Table 4 ). The systolic blood pressure before exercise testing was similar to that during the control exercise test on the 4 study days; but it was significantly lower at both 2 and 6 hours after isosorbide dinitrate. The systolic blood pressure decreased by 11% from the control values 2 hours after isosorbide dinitrate during this phase of the study, which was significantly less than the 25% decrease noted during the acute phase (p < 0.05). Sublingual nitroglycerin induced a significant decrease in systolic blood pressure at 2 112 and 6 112 hours after both oral isosorbide dinitrate and placebo. At 6 1/2 hours, the decrease in systolic blood pressure after nitroglycerin was 19% in the patients receiving placebo, and 14% in those receiving sustained isosorbide dinitrate. Neither these changes nor the absolute values of blood pressure after nitroglycerin administration were significantly different.
Rate-pressure product (Table 4 ). The exercise ratepressure product at moderate angina was not significantly different on the 4 study days during the control period. Administration of isosorbide dinitrate did not affect the exercise rate-pressure product at this end point, but after nitroglycerin, the rate-pressure product increased significantly at 6 1/2 hours but not at 2 112 hours after oral placebo. Sublingual nitroglycerin did not affect the rate-pressureproduct at either time after oral isosorbide dinitrate. Abbreviations as in Table 2 Discussion Circulatory tolerance to nitrates. The present study evaluates the development of tolerance to isosorbide dinitrate and the interactions between isosorbide dinitrate and nitroglycerin on the hemodynamic changes and exercise duration in patients with angina pectoris secondary to coronary artery disease. The phenomenon of circulatory tolerance to nitrates has been well studied in animals. A 10-to 15-fold shift in the blood pressure dose-response curve to nitroglycerin has been produced in dogs (13, 17) , rabbits (11, 14) and rats (16, 17) after repeated intravenous or subcutaneous administration. In human beings, tolerance to nitrate headaches in industrial workers has been well documented (26) (27) (28) and recent studies have shown attenuation of the hemodynamic (7, 24) and antianginal (7) effects of isosorbide dinitrate.
We have previously shown (24) that after the same dose of isosorbide dinitrate, plasma concentrations are significantly higher during sustained than during acute therapy. In the present study, hemodynamic responses were diminished and there was less improvement in exercise time during the sustained phase of therapy. These attenuated responses, despite presumably higher plasma isosorbide dinitrate levels, indicate tolerance.
The improvement in exercise duration at 2 hours but not at 6 hours after isosorbide dinitrate during the sustained phase of the study was similar to that of our previous report (7) , but different from that reported by Danahy and Aronow (22) , who noted prolonged exercise duration at 5 hours. They also observed that the hemodynamic effects of isosorbide dinitrate persisted longer than the antianginal effect. Our findings support this observation.
In animal experiments, Needleman and Johnson (18) found that all organic nitrates induced tolerance to the circulatory effects of nitroglycerin, with isosorbide dinitrate resulting in the least tolerance. In human beings, the results have been conflicting. In volunteers given sublingual nitroglycerin, Schelling and Lasagna (20) found that the circulatory effects were markedly but not completely reduced after therapy with pentaerythrityl tetranitrate. Previous studies from our laboratory (24) showed that the reduction in blood pressure induced by nitroglycerin was markedly attenuated during sustained therapy with isosorbide dinitrate. In contrast, Aronow and Chesluk (21) were unable to show the development of circulatory tolerance to nitroglycerin during sustained therapy with sublingual isosorbide dinitrate. However, the dose of isosorbide dinitrate (5 mg, 4 times daily) may have been inadequate to induce significant tolerance. Danahy and Aronow (22) also failed to show cross-tolerance to the circulatory and antianginal effects of nitroglycerin during oral isosorbide dinitrate therapy. However, they studied the effects of nitroglycerin 14 hours after the last dose of isosorbide dinitrate.
Mechanism of different effects of nitroglycerin 2 1/2 and 6 1/2 hours after isosorbide dinitrate. In the present study, the decrease in blood pressure and improvement in exercise tolerance after nitroglycerin at 6 1/2, but not at 2 1/2 hours after isosorbide dinitrate remains to be understood. The absence of such changes at 2 1/2 hours has two possible explanations. First, it could indicate cross-tolerance between isosorbide dinitrate and nitroglycerin. Second, the hypotensive effect could be limited by homeostatic responses and the improvement in exercise limited by the ability to improve the oxygen supply-demand relation. Thus, the failure to alter these variables at 2 1/2 hours with nitroglycerin could mean that the maximal nitrate effect had already been achieved by isosorbide dinitrate. In this situation, it would be impossible to demonstrate cross-tolerance.
Six and one-half hours after oral isosorbide dinitrate, the administration of nitroglycerin led to significant changes in blood pressure and exercise duration. This could be interpreted as a demonstration of the absence of cross-tolerance between these two nitrates. Indeed, such a conclusion was reached by Lee et al (23) , who found improvement in exercise time after nitroglycerin administration 6 hours after administering oral isosorbide dinitrate; however, this may not be a valid explanation for these findings. There is clear evidence (24) of the development of tolerance during sustained oral isosorbide dinitrate therapy. Despite such tolerance, 2 hours after subsequent oral isosorbide dinitrate administration, there was a decrease in blood pressure, although less marked than during acute therapy, and a prolongation of walking time. These findings indicate that nitrate tolerance was not complete. It appears that after subsequent doses, rising plasma isosorbide dinitrate levels induce further vascular effects that lead to reductions in blood pressure and improvement in exercise duration. The nitroglycerin response seen 6 1/2 hours after isosorbide dinitrate could indicate a similar phenomenon. Such a response does not confirm or disprove cross-tolerance between these two organic nitrates. An assessment of the hemodynamic and antianginal effects of sublingual isosorbide dinitrate during sustained oral isosorbide dinitrate therapy may clarify this issue.
There is some hemodynamic evidence in our study to suggest the development of cross-tolerance in that the decrease in systolic blood pressure and the increase in treadmill walking time after nitroglycerin were less when the patients were receiving oral isosorbide dinitrate than when receiving oral placebo. Though not statistically significant, this trend would suggest the development of cross-tolerance between the two drugs.
Does nitrate cross-tolerance exist? It is difficult to determine whether cross-tolerance exists, but our observations are compatible with such a phenomenon. Because it is assumed that organic nitrates have similar mechanisms of action, and animal studies (18) have demonstrated that cross-tolerance does occur, one would expect this to develop in human beings as well . The current investigation demonstrates the development of tolerance to isosorbide dinitrate and is in accordance with the presence of cross-tolerance between isosorbide dinitrate and nitroglycerin .
